GLP-1受体的细胞外表面是偏差激进主义的分子触发器
Denise Wootten1, Christopher A Reynolds2, Kevin J Smith2
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Cell
|June 18, 2016
概括
在G蛋白合受体 (GPCRs) 中,可以利用带导向的信号偏差来获得更安全的治疗方法. 了解连接体结合如何启动受体激活和偏向信号是药物设计的关键.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 结构生物学 结构生物学
背景情况:
- 在G蛋白合受体 (GPCRs) 中的带导向信号偏差为通过选择性调节细胞反应来开发更安全的治疗方法提供了一个有希望的途径.
- 了解将连接联体结合与细胞内信号的分子机制对于有效利用信号偏差至关重要.
- 乙类GPCRs的激活涉及的N端与受体核心的相互作用.
研究的目的:
- 阐明B类GPCRs中的分子事件合连接物结合到细胞内信号.
- 将受体修饰的功能后果映射到受体-连接体复合体的三维模型上.
- 提供对受体激活启动的分子洞察力和偏向性激励的机制基础.
主要方法:
- 利用先进的分析技术,将特定途径的信号效应与激动剂 afinity 的修改区分开来.
- 将受体修饰的功能后果映射到受体-连接体复合体的3D模型上.
- 研究了受体激活的启动和偏向的激动机制.
主要成果:
- 激动剂可以与受体细胞外面的不同区域相互作用,以引起特定的效应器合和偏差信号.
- 先进的分析方法成功地将对特定途径信号的影响与激动剂亲和力变化分开.
- 受体修饰的功能后果被映射到3D受体-连接体复杂模型上.
结论:
- 该研究提供了对GPCR激活的启动和偏见性激进主义的机制基础的分子洞察.
- 不同的激素激素与受体细胞外面的相互作用导致不同的效应器合和偏差信号.
- 这些发现为治疗应用的偏向激动剂的合理设计奠定了基础.
相关概念视频
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:09GPCRs Regulate Adenylyl Cylase Activity
8.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.2K
01:30Transducer Mechanism: G Protein–Coupled Receptors
7.2K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
7.2K
01:12GPCR Desensitization
8.6K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.6K
01:30Spare Receptors
4.8K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.8K
01:29The Two-State Receptor Model
3.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
3.4K